Ammonia-lowering strategies for the treatment of hepatic encephalopathy

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 3, 2012, Pages 321-331

  Rose, C F ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; 6 DIAZO 5 OXONORLEUCINE; ACARBOSE; AMMONIA; AST 120; BENZOIC ACID; BENZOIC ACID PLUS PHENYLACETIC ACID; BIS 2[5 PHENYLACETAMIDO 1,2,4 THIADIAZOL 2 YL]ETHYLSULFIDE; BRANCHED CHAIN AMINO ACID; ENZYME INHIBITOR; GLUTAMATE AMMONIA LIGASE; GLUTAMINE; GLYCEROL PHENYLBUTYRATE; LACTULOSE; METRONIDAZOLE; NEOMYCIN; ORNITHINE ASPARTATE; ORNITHINE PHENYLACETATE; PHENYLACETIC ACID; PROBIOTIC AGENT; RIFAXIMIN; THDP17; UNCLASSIFIED DRUG; VANCOMYCIN;

ABSENCE OF SIDE EFFECTS; AMIDATION; ANTIBIOTIC RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DEAMINATION; DRUG TARGETING; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; NEPHROTOXICITY; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PATHOGENESIS; PRIORITY JOURNAL; SIDE EFFECT; SKELETAL MUSCLE;

AMMONIA; BRAIN; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERAMMONEMIA; LIVER;

EID: 84865442957     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.112     Document Type: Article

References (75)

1. Stewart, C.A. & Smith, G.E. Minimal hepatic encephalopathy. Nat. Clin. Pract. Gastroenterol. Hepatol. 4, 677-685 (2007). (Pubitemid 350193817)
2. Poordad, F.F. Review article: the burden of hepatic encephalopathy. Aliment. Pharmacol. Ther. 25 (suppl. 1), 3-9 (2007). (Pubitemid 46148239)
3. Bajaj, J.S. Review article: the modern management of hepatic encephalopathy. Aliment. Pharmacol. Ther. 31, 537-547 (2010).
4. Nef, G. Pharmacoeconomics of hepatic encephalopathy. Pharmacotherapy 30, 28S-32S (2010).
5. Bosoi, C.R. & Rose, C.F. Identifying the direct efects of ammonia on the brain. Metab. Brain Dis. 24, 95-102 (2009).
6. Felipo, V. & Butterworth, R.F. Neurobiology of ammonia. Prog. Neurobiol. 67, 259-279 (2002). (Pubitemid 35229984)
7. Wright, G., Noiret, L., Olde Damink, S.W. & Jalan, R. Interorgan ammonia metabolism in liver failure: the basis of current and future therapies. Liver Int. 31, 163-175 (2011).
8. Bosoi, C.R. et al. Systemic oxidative stress is implicated in the pathogenesis of brain edema in rats with chronic liver failure. Free Radic. Biol. Med. 52, 1228-1235 (2012).
9. Oria, M., Romero-Giménez, J., Arranz, J.A., Riudor, E., Raguer, N. & Córdoba, J. Ornithine phenylacetate prevents disturbances of motor-evoked potentials induced by intestinal blood in rats with portacaval anastomosis. J. Hepatol. 56, 109-114 (2012).
10. Ytrebø, L.M. et al. L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology 50, 165-174 (2009).
11. Keiding, S., Sørensen, M., Bender, D., Munk, O.L., Ott, P. & Vilstrup, H. Brain metabolism of 13N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology 43, 42-50 (2006). (Pubitemid 43733590)
12. Sørensen, M. & Keiding, S. New fndings on cerebral ammonia uptake in HE using functional (13)N-ammonia PET. Metab. Brain Dis. 22, 277-284 (2007). (Pubitemid 47624318)
13. Rose, C., Kresse, W. & Kettenmann, H. Acute insult of ammonia leads to calcium-dependent glutamate release from cultured astrocytes, an efect of pH. J. Biol. Chem. 280, 20937-20944 (2005). (Pubitemid 40805650)
14. Davies, N.A. et al. L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats. Hepatology 50, 155-164 (2009).
15. Rovira, A., Alonso, J. & Córdoba, J. MR imaging fndings in hepatic encephalopathy. AJNR. Am. J. Neuroradiol. 29, 1612-1621 (2008).
16. Chatauret, N., Zwingmann, C., Rose, C., Leibfritz, D. & Butterworth, R.F. Efects of hypothermia on brain glucose metabolism in acute liver failure: a H/C-nuclear magnetic resonance study. Gastroenterology 125, 815-824 (2003). (Pubitemid 37070699)
17. Schiano, T. Complications of chronic liver disease. In Current Diagnosis and Treatment in Gastroenterology (eds. Friedman, S., Grendell, J. & McQuaid, K.) 639-663 (Lange Medical Books/McGraw-Hill, 2003).
18. Kundra, A., Jain, A., Banga, A., Bajaj, G. & Kar, P. Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension. Clin. Biochem. 38, 696-699 (2005). (Pubitemid 41019565)
19. Shawcross, D.L., Davies, N.A., Williams, R. & Jalan, R. Systemic infammatory response exacerbates the neuropsychological efects of induced hyperammonemia in cirrhosis. J. Hepatol. 40, 247-254 (2004). (Pubitemid 38115829)
20. Montoliu, C. et al. 3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis. Am. J. Gastroenterol. 106, 1629-1637 (2011).
21. Bémeur, C., Desjardins, P. & Butterworth, R.F. Role of nutrition in the management of hepatic encephalopathy in end-stage liver failure. J. Nutr. Metab. 2010, 489823 (2010).
22. van Leeuwen, P.A., van Berlo, C.L. & Soeters, P.B. New mode of action for lactulose. Lancet 1, 55-56 (1988). (Pubitemid 18017231)
23. Sharma, P., Agrawal, A., Sharma, B.C. & Sarin, S.K. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J. Gastroenterol. Hepatol. 26, 996-1003 (2011).
24. Als-Nielsen, B., Gluud, L.L. & Gluud, C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 328, 1046 (2004).
25. Prasad, S., Dhiman, R.K., Duseja, A., Chawla, Y.K., Sharma, A. & Agarwal, R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45, 549-559 (2007). (Pubitemid 46450607)
26. Teperman, L.W. & Peyregne, V.P. Considerations on the impact of hepatic encephalopathy treatments in the pretransplant setting. Transplantation 89, 771-778 (2010).
27. Conn, H.O. et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 72, 573-583 (1977). (Pubitemid 8097592)
28. Morgan, M.H., Read, A.E. & Speller, D.C. Treatment of hepatic encephalopathy with metronidazole. Gut 23, 1-7 (1982). (Pubitemid 12170168)
29. Tarao, K. et al. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 31, 702-706 (1990). (Pubitemid 20209045)
30. Greenberg, L.H. & Momary, H. Audiotoxicity and nephrotoxicity due to orally administered neomycin. JAMA 194, 827-828 (1965).
31. Heaney, C.J., Campeau, N.G. & Lindell, E.P. MR imaging and difusion-weighted imaging changes in metronidazole (Flagyl)-induced cerebellar toxicity. AJNR. Am. J. Neuroradiol. 24, 1615-1617 (2003). (Pubitemid 37151730)
32. Loft, S., Sonne, J., Døssing, M. & Andreasen, P.B. Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand. J. Gastroenterol. 22, 117-123 (1987). (Pubitemid 17001035)
33. Smith, T.L. et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N. Engl. J. Med. 340, 493-501 (1999).
34. Bass, N.M. et al. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 362, 1071-1081 (2010).
35. Mas, A. et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J. Hepatol. 38, 51-58 (2003). (Pubitemid 36078524)
36. Pedretti, G., Calzetti, C., Missale, G. & Fiaccadori, F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital. J. Gastroenterol. 23, 175-178 (1991).
37. Leevy, C.B. & Phillips, J.A. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig. Dis. Sci. 52, 737-741 (2007).
38. Malaguarnera, M., Greco, F., Barone, G., Gargante, M.P., Malaguarnera, M. & Toscano, M.A. Bifdobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig. Dis. Sci. 52, 3259-3265 (2007). (Pubitemid 47512537)
39. Bajaj, J.S. et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am. J. Gastroenterol. 103, 1707-1715 (2008).
40. McGee, R.G., Bakens, A., Wiley, K., Riordan, S.M. & Webster, A.C. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst. Rev., CD008716 (2011).
41. Solga, S.F. Probiotics can treat hepatic encephalopathy. Med. Hypotheses 61, 307-313 (2003). (Pubitemid 36976202)
42. Bajaj, J.S. et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G168-G175 (2012).
43. Hatakeyama, S. et al. Efect of an oral adsorbent, AST-120, on dialysis initiation and survival in patients with chronic kidney disease. Int. J. Nephrol. 2012, 376128 (2012).
44. Tack, J.F., Miner, P.B. Jr, Fischer, L. & Harris, M.S. Randomised clinical trial: the safety and efcacy of AST-120 in non-constipating irritable bowel syndrome-a double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 34, 868-877 (2011).
45. Shen, B. et al. The efcacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis. Am. J. Gastroenterol. 104, 1468-1474 (2009).
46. Bosoi, C.R., Parent-Robitaille, C., Anderson, K., Tremblay, M. & Rose, C.F. AST-120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile duct-ligated rats. Hepatology 53, 1995-2002 (2011).
47. Pockros, P. et al. Phase 2, multicenter, randomized study of AST-120 (spherical carbon adsorbent) vs. lactulose in the treatment of low-grade hepatic encephalopathy. J. Hepatol. 50, S43-S44 (2009).
48. Batshaw, M.L. et al. Treatment of inborn errors of urea synthesis: activation of alternative pathways of waste nitrogen synthesis and excretion. N. Engl. J. Med. 306, 1387-1392 (1982). (Pubitemid 12114405)
49. Sushma, S., Dasarathy, S., Tandon, R.K., Jain, S., Gupta, S. & Bhist, M.S. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 16, 138-144 (1992).
50. Maswoswe, S.M. & Tremblay, G.C. Biosynthesis of hippurate, urea and pyrimidines in the fatty liver: studies with rats fed orotic acid or a diet defcient in choline and inositol, and with genetically obese (Zucker) rats. J. Nutr. 119, 273-279 (1989). (Pubitemid 19080838)
51. Honda, S. et al. Successful treatment of severe hyperammonemia using sodium phenylacetate powder prepared in hospital pharmacy. Biol. Pharm. Bull. 25, 1244-1246 (2002). (Pubitemid 39655176)
52. Lichter-Konecki, U. et al. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate. Mol. Genet. Metab. 103, 323-329 (2011).
53. Romero-Gómez, M., Jover, M., Galán, J.J. & Ruiz, A. Gut ammonia production and its modulation. Metab. Brain Dis. 24, 147-157 (2009).
54. Romero-Gómez, M. et al. Variations in the promoter region of the glutaminase gene and the development of hepatic encephalopathy in patients with cirrhosis: a cohort study. Ann. Intern. Med. 153, 281-288 (2010).
55. Gentile, S. et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin. Gastroenterol. Hepatol. 3, 184-191 (2005). (Pubitemid 40220314)
56. Marchesini, G. et al. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized double-blind casein-controlled trial. The Italian Multicenter Study Group. J. Hepatol. 11, 92-101 (1990). (Pubitemid 20250834)
57. Als-Nielsen, B., Koretz, R.L., Kjaergard, L.L. & Gluud, C. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst. Rev., CD001939 (2003).
58. Marchesini, G. et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 124, 1792-1801 (2003). (Pubitemid 36666776)
59. Chatauret, N., Desjardins, P., Zwingmann, C., Rose, C., Rao, K.V. & Butterworth, R.F. Direct molecular and spectroscopic evidence for increased ammonia removal capacity of skeletal muscle in acute liver failure. J. Hepatol. 44, 1083-1088 (2006).
60. Dam, G. et al. Branched-chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G269-G277 (2011).
61. Rose, C. et al. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efcacy and mechanism of action. Metab. Brain Dis. 13, 147-157 (1998). (Pubitemid 28350749)
62. Rose, C., Michalak, A., Rao, K.V., Quack, G., Kircheis, G. & Butterworth, R.F. L-ornithine-L-aspartate lowers plasma and cerebrospinal fuid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 30, 636-640 (1999). (Pubitemid 29409406)
63. Kircheis, G. et al. Therapeutic efcacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 25, 1351-1360 (1997). (Pubitemid 27250753)
64. Jiang, Q., Jiang, X.H., Zheng, M.H. & Chen, Y.P. L-Ornithine-l- aspartate in the management of hepatic encephalopathy: a meta-analysis. J. Gastroenterol. Hepatol. 24, 9-14 (2009).
65. Acharya, S.K., Bhatia, V., Sreenivas, V., Khanal, S. & Panda, S.K. Efficacy of L-ornithine L-aspartate in acute liver failure: a double-blind, randomized, placebo-controlled study. Gastroenterology 136, 2159-2168 (2009).
66. Bhatia, V., Singh, R. & Acharya, S.K. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut 55, 98-104 (2006). (Pubitemid 41820642)
67. Malaguarnera, M., Pistone, G., Elvira, R., Leotta, C., Scarpello, L. & Liborio, R. Efects of L-carnitine in patients with hepatic encephalopathy. World J. Gastroenterol. 11, 7197-7202 (2005). (Pubitemid 43154020)
68. Malaguarnera, M. et al. Efects of L-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. Dig. Dis. Sci. 51, 2242-2247 (2006).
69. del Olmo, J.A. et al. Efect of L-carnitine upon ammonia tolerance test in cirrhotic patients. Adv. Exp. Med. Biol. 272, 197-208 (1990).
70. Sharma, P., Sharma, B.C., Puri, V. & Sarin, S.K. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur. J. Gastroenterol. Hepatol. 20, 506-511 (2008). (Pubitemid 351667890)
71. Malaguarnera, M. et al. Branched chain amino acids supplemented with L-acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study. Eur. J. Gastroenterol. Hepatol. 21, 762-770 (2009).
72. Enns, G.M., Berry, S.A., Berry, G.T., Rhead, W.J., Brusilow, S.W. & Hamosh, A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N. Engl. J. Med. 356, 2282-2292 (2007). (Pubitemid 46849158)
73. Mendenhall, C.L., Rouster, S., Marshall, L. & Weesner, R. A new therapy for portal systemic encephalopathy. Am. J. Gastroenterol. 81, 540-543 (1986). (Pubitemid 16097218)
74. Jalan, R., Wright, G., Davies, N.A. & Hodges, S.J. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med. Hypotheses 69, 1064-1069 (2007). (Pubitemid 47430227)
75. Zieve, L., Lyftogt, C. & Raphael, D. Ammonia toxicity: comparative protective efect of various arginine and ornithine derivatives, aspartate, benzoate, and carbamyl glutamate. Metab. Brain Dis. 1, 25-35 (1986). (Pubitemid 17119150)